Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Idiopathic pulmonary fibrosis is a progressive lung disease with a high mortality rate. Because the signaling pathways activated by several tyrosine kinase receptors have been shown to be involved in lung fibrosis, it has been suggested that the inhibition of these receptors may slow the progression of idiopathic pulmonary fibrosis. METHODS: In a 12-month, phase 2 trial, we assessed the efficacy and safety of four different oral doses of the tyrosine kinase inhibitor BIBF 1120 as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Secondary end points included acute exacerbations, quality of life (measured with the St. George's Respiratory Questionnaire [SGRQ]), and total lung capacity. RESULTS: A total of 432 patients underwent randomization to receive one of four doses of BIBF 1120 (50 mg once a day, 50 mg twice a day, 100 mg twice a day, or 150 mg twice a day) or placebo. In the group receiving 150 mg of BIBF 1120 twice a day, FVC declined by 0.06 liters per year, as compared with 0.19 liters per year in the placebo group, a 68.4% reduction in the rate of loss with BIBF 1120 (P = 0.06 with the closed testing procedure for multiplicity correction; P = 0.01 with the hierarchical testing procedure). This dose also resulted in a lower incidence of acute exacerbations, as compared with placebo (2.4 vs. 15.7 per 100 patient-years, P = 0.02) and a small decrease in the SGRQ score (assessed on a scale of 0 to 100, with lower scores indicating better quality of life) as compared with an increase with placebo (-0.66 vs. 5.46, P = 0.007). Gastrointestinal symptoms (which led to more discontinuations in the group receiving 150 mg twice a day than in the placebo group) and increases in levels of liver aminotransferases were more frequent in the group receiving 150 mg of BIBF 1120 twice daily than in the placebo group. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, BIBF 1120 at a dose of 150 mg twice daily, as compared with placebo, was associated with a trend toward a reduction in the decline in lung function, with fewer acute exacerbations and preserved quality of life. (Funded by Boehringer Ingelheim; ClinicalTrials.gov number, NCT00514683 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The Bayesian approach incorporated dynamic borrowing of historical placebo data from several external IPF trials, including the ASCEND, INPULSIS, and TOMORROW studies (Figures E2 and E3).2,3,13”
From Deupirfenidone Compared with Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis (ELEVATE-IPF): a Phase 2b Randomized Placebo-Controlled Trial (2026) · cites this paper as [13]
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
The St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Selman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786
Self-citationClinical course and prediction of survival in idiopathic pulmonary fibrosis
Ley, B., Collard, H. R., & King, T. E. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201006-0894ci · Cited by 1,765
Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
The Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationBois, R. M. D., Weycker, D., Albera, C., Bradford, W. Z., Costabel, U., Kartashov, A., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201007-1179oc · Cited by 465
Self-citation
Cited by
Items 801–900 of 1,000
Mendoza, F. A., Allawh, T., & Jiménez, S. A. (2022) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/am4nmv · Cited by 5
Clinical significance of high monocyte counts for the continuous treatment with nintedanib
Tsuneyoshi, S., Zaizen, Y., Tominaga, M., Matama, G., Umemoto, S., Ohno, S., Takaki, R., Yano, R., Murotani, K., Okamoto, M., et al. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02536-y · Cited by 4
Planas‐Cerezales, L., Fabbri, L., & Pearmain, L. (2023) · Breathe · doi:10.1183/20734735.0090-2023 · Cited by 4
Takuma, S., Suzuki, Y., Kono, M., Hasegawa, H., Hashimoto, D., Yokomura, K., Mori, K., Shimizu, M., Inoue, Y., Yasui, H., et al. (2024) · Respiratory Medicine · doi:10.1016/j.rmed.2024.107542 · Cited by 4
Park, A.-M., Hayakawa, S., Honda, E., Mine, Y., Yoshida, K., & Munakata, H. (2011) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2011.12.012 · Cited by 4
Experimentation with aerosol bonsetan, pirfenidone, treprostinil and sidenafil.
Huang, H., Zarogoulidis, P., Lampaki, S., Organtzis, J., Petridis, D., Porpodis, Κ., Papaiwannou, A., Karageorgiou, V., Pitsiou, G., Kioumis, I. P., et al. (2014) · PubMed Central · doi:10.3978/j.issn.2072-1439.2014.08.38 · Cited by 4
Die idiopathische Lungenfibrose
Prasse, A. (2015) · Pneumologie · doi:10.1055/s-0034-1393036 · Cited by 5
Treatment of Idiopathic Pulmonary Fibrosis
Nathan, S. D., Brown, A. W., & King, C. S. (2016) · Springer eBooks · doi:10.1007/978-3-319-32794-5_7 · Cited by 4
Therapie der systemischen Sklerose-assoziierten interstitiellen Lungenerkrankung
Prasse, A., Bonella, F., Müller‐Ladner, U., Witte, T., Hunzelmann, N., & Distler, J. H. W. (2019) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-019-00724-y · Cited by 4
Guleria, R., Chaudhry, D., Singh, V., Kumar, R., Nangia, V., Dhar, R., Agarwal, R., Jindal, A., Madan, K., Behera, D., et al. (2022) · The Indian Journal of Chest Diseases and Allied Sciences · doi:10.5005/ijcdas-60-2-91 · Cited by 7
Savale, L., Bertoletti, L., & Cottin, V. (2013) · Respiration · doi:10.1159/000348389 · Cited by 4
Shimizu, T., Sagara, A., Fukuchi, Y., & Muto, A. (2024) · Oncology Letters · doi:10.3892/ol.2024.14254 · Cited by 3
Idiopathic pleuroparenchymal fibroelastosis: diagnosis and management
Ishii, H., Kinoshita, Y., Hamada, N., Fujita, M., & Kushima, H. (2025) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2025.2499651 · Cited by 3
Yu, W.-K., Yang, Y.-P., Shen, H., Shen, H.-C., Chiou, S.-H., Ko, Y., Su, V. Y., Su, V. Y.-F., & Yang, K. (2025) · Respiratory Investigation · doi:10.1016/j.resinv.2025.07.005 · Cited by 3
Miceli, V., Callari, A., Calzolari, E., Castelbuono, S., Claudia, C., Lanzarone, N., Martino, L., Conaldi, P. G., Pinzani, M., & Vitulo, P. (2025) · Scientific Reports · doi:10.1038/s41598-025-12952-1 · Cited by 3
Bolger, G. B. (2025) · Life · doi:10.3390/life15101600 · Cited by 6
Zheng, C., Ding, W., Sun, Y., Wang, Y., & Zhang, Y. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s576680 · Cited by 3
Progressive pulmonary fibrosis: a state-of-the-art review
Cottin, V., Brown, K. K., Flaherty, K. R., Kolb, M. R. J., Lynch, D. A., Oldham, J. M., Valenzuela, C., Wijsenbeek, M. S., & Wells, A. U. (2026) · European Respiratory Journal · doi:10.1183/13993003.01557-2025 · Cited by 4
Self-citationCollard, H. R., Morris, A., Daley, C. L., Humbert, M. J. C., & Meyer, K. C. (2012) · Proceedings of the American Thoracic Society · doi:10.1513/pats.201207-035tt · Cited by 3
Pulmonary Complications of Radiation Therapy
Lee, D. J., Gelblum, D. Y., & Lee, N. Y. (2017) · Respiratory medicine · doi:10.1007/978-3-319-69620-1_15 · Cited by 3
Transcriptional factor RUNX1: A potential therapeutic target for fibrotic pulmonary disease
LIU, J., WANG, F., YUAN, B., & Luo, F. (2023) · Biocell · doi:10.32604/biocell.2023.026148 · Cited by 3
Amin, R., Pandey, R., Vaishali, K., Acharya, V. K., Sinha, M. K., & Kumar, N. (2023) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557523666230816090112 · Cited by 4
Potential therapeutic targets of fibrosis in inflammatory rheumatic diseases
Jiang, S., Desmarais, J., Chu, C., & Zhu, J. (2024) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2024.101945 · Cited by 3
Clinical implications of nintedanib pharmacokinetics in patients with pulmonary fibrosis
Agema, B. C., Berrich, M., Seuren, L., Sassen, S. D. T., Miedema, J. R., Koch, B. C. P., Wijsenbeek, M. S., Koolen, S. L. W., Mathijssen, R. H. J., & Veerman, G. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117341 · Cited by 3
Perioperative nintedanib for lung resection in patients with idiopathic pulmonary fibrosis
Sumiya, R., Banno, T., Ueno, H., Hirayama, S., & Suzuki, K. (2025) · Molecular and Clinical Oncology · doi:10.3892/mco.2025.2854 · Cited by 3
Wang, W., Chen, S., Xi, Z., Si, Y., Liu, Y., Chen, J., Wang, B., Zhu, D., & Gong, L. (2025) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2024-0527oc · Cited by 4
Cottin, V., Wijsenbeek, M. S., Bonella, F., & Vancheri, C. (2014) · Clinical Investigation · doi:10.4155/cli.14.23 · Cited by 4
Acute exacerbation of idiopathic pulmonary fibrosis
Avdeev, S. N. (2018) · PULMONOLOGIYA · doi:10.18093/0869-0189-2018-28-4-469-482 · Cited by 3
Nintedanib in Severe Idiopathic Pulmonary Fibrosis: Effectiveness through Compassion
Tzouvelekis, A., & Bouros, D. E. (2018) · Respiration · doi:10.1159/000488647 · Cited by 4
Pharmacological Interventions for Pulmonary Involvement in Rheumatic Diseases
Kang, E. H., & Song, Y. W. (2021) · Pharmaceuticals · doi:10.3390/ph14030251 · Cited by 5
Beyond TGFβ1 - novel treatment strategies targeting lung fibrosis
Sim, C., Lamanna, E., Cirnigliaro, F., & Lam, M. (2021) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2021.106090 · Cited by 3
Challenges in the Diagnosis and Management of Patients with Fibrosing Interstitial Lung Disease
Tolle, L. B. (2022) · Case Reports in Pulmonology · doi:10.1155/2022/9942432 · Cited by 5
Tseng, C.-M., Chen, M.-Y., Kao, C.-Y., & Tao, C.-W. (2022) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000719 · Cited by 5
Avdeev, S. N., Ilkovich, M. M., Terpigorev, S. A., Moiseev, S. V., & Tyurin, I. E. (2023) · Life · doi:10.3390/life13020483 · Cited by 5
Loss of EGF receptor polarity enables homeostatic imbalance in epithelial-cell models
Carlin, C. R., & Ngalula, S. (2023) · Molecular Biology of the Cell · doi:10.1091/mbc.e23-04-0133 · Cited by 4
Nintedanib-associated enterocolitis with intractable diarrhea: a case report
Miyaguchi, K., Tsuzuki, Y., Uemuara, H., Ishizawa, K., Shinomiya, S., Matsumoto, H., Shiomi, R., Ohgo, H., Nagata, M., Nakamoto, H., et al. (2023) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-023-01894-8 · Cited by 3
Zhang, X., Zhang, K., Zhao, N., Xi, N., & Zhao, T. (2024) · Journal of Medical Case Reports · doi:10.1186/s13256-024-04790-y · Cited by 3
Emerging Therapeutic Targets and Therapies in Idiopathic Pulmonary Fibrosis
Parvathaneni, V., Shukla, S. K., & Gupta, V. (2018) · Molecular and translational medicine · doi:10.1007/978-3-319-98143-7_8 · Cited by 4
The Role of Tyrosine Kinases in the Pathogenesis and Treatment of Lung Disease
Lam, J., & Stewart, J. (2012) · InTech eBooks · doi:10.5772/37901 · Cited by 3
Practical Issues and Challenges in Idiopathic Pulmonary Fibrosis
Cottin, V., & Camus, P. (2013) · Respiration · doi:10.1159/000353571 · Cited by 3
Pitfalls in developing new compounds for idiopathic pulmonary fibrosis
Nathan, S. D., & Martínez, F. J. (2017) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000407 · Cited by 3
Behr, J., Günther, A., Kreuter, M., Koschel, D., Prasse, A., Pfeifer, M. A., & Costabel, U. (2017) · Pneumologie · doi:10.1055/s-0043-109856 · Cited by 5
Self-citationIdiopathic Pulmonary Fibrosis: What Is the Best Treatment?
Martínez, F. J., Kaner, R. J., & Wu, X. (2017) · Barcelona Respiratory Network · doi:10.23866/brnrev:2017-m0041 · Cited by 3
Ho, R. S., Souza, C., Oliveira, C., Lisondo, C., & Alves, M. R. (2017) · Jornal Brasileiro de Economia da Saúde · doi:10.21115/jbes.v9.suppl1.89-95 · Cited by 3
Pharmacologic Treatment of IPF
Smargiassi, A., Pasciuto, G., Conte, E. G., Andreani, M., Marra, R., & Richeldi, L. (2018) · Respiratory medicine · doi:10.1007/978-3-319-99975-3_13 · Cited by 3
Self-citationLeft ventricular dysfunction in an idiopathic pulmonary fibrosis patient on nintedanib
Imai, R., & Tomishima, Y. (2020) · Respirology Case Reports · doi:10.1002/rcr2.533 · Cited by 3
Cottin, V., Crestani, B., Cadranel, J. L., Cordier, J. F., Marchand-Adam, S., Prévôt, G., Wallaert, B., Bergot, E., Camus, P., Dalphin, J., et al. (2017) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2017.07.019 · Cited by 3
Cottin, V., & Valenzuela, C. (2016) · European Respiratory Society eBooks · doi:10.1183/2312508x.10006115 · Cited by 3
Targeted treatment of idiopathic pulmonary fibrosis: one step at a time
Richeldi, L. (2016) · European Respiratory Journal · doi:10.1183/13993003.00389-2016 · Cited by 3
Self-citationCould Cryo-Biopsies Lead Bronchoscopy Into the Ice Age?
Pastis, N. J., & Silvestri, G. A. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.04.008 · Cited by 3
Idiopathic pulmonary fibrosis: time for greater expectations?
Wuyts, W. A., & Cottin, V. (2018) · European Respiratory Journal · doi:10.1183/13993003.01312-2018 · Cited by 3
Progressive fibrosing interstitial lung disease: we know it behaves badly, but what does that mean?
Wongkarnjana, A., & Ryerson, C. J. (2020) · European Respiratory Journal · doi:10.1183/13993003.00894-2020 · Cited by 3
The human pathome shows sex specific aging patterns post-developmentPreprint
Ezra, M. B., Garbrecht, J. B., Rasmussen, N., Heckenbach, I., Petr, M. A., Bakula, D., Mortensen, L. H., & Scheibye‐Knudsen, M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.27.530179 · Cited by 3
Wang, Y., Zhang, Z., Zhang, H., Xu, L., Huang, S., Wen, Y., Zhuang, Z., Li, X., Li, X. J., & Li, X. J. (2025) · Scientific Reports · doi:10.1038/s41598-025-02579-7 · Cited by 2
Impact of medications on lung function in fibrotic hypersensitivity pneumonitis
Abe, T., Okamoto, T., Shimamura, T., Ejima, M., Sonoda, S., Shirai, T., Ishizuka, M., Furusawa, H., Tateishi, T., Hanazawa, R., et al. (2025) · Respiratory Investigation · doi:10.1016/j.resinv.2025.09.001 · Cited by 2
Andugulapati, S. B., Kambhampati, V., & Kumar, H. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00322 · Cited by 2
The role of epigenetic regulation in idiopathic pulmonary fibrosis
Li, R. M., Stentenbach, M., Tan, D. B. A., Ludewick, H. P., Walters, E. H., Clynick, B., & Moodley, Y. P. (2025) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00030.2025 · Cited by 3
Zeng, W., Hua, X., Wang, Z., Li, K., Yin, Y., Li, X., Dong, S., & Ma, M. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02587 · Cited by 2
Zhou, L., Zhu, M., Chen, L., Wang, Y., Xu, L., Liu, J., Chen, L., Tuo, Y., Meilang, Q., & Luo, F. (2026) · BMC Pulmonary Medicine · doi:10.1186/s12890-026-04126-0 · Cited by 2
Kaburaki, S., Tanaka, T., Kamio, K., Tanaka, Y., Taniuchi, N., Kasahara, K., & Seike, M. (2026) · Annals of the American Thoracic Society · doi:10.1093/annalsats/aaoag069 · Cited by 2
Rosas, I. O., McDowell-Sanchez, A. K., Sanchez, S., Cala-García, J., Cohen, A. R. W., Ruiz-Echartea, E., Ochsner, S. A., Kraushaar, D. C., Celada, L. J., Sun, D., et al. (2026) · Journal of Clinical Investigation · doi:10.1172/jci197651 · Cited by 4
The cardiovascular system in idiopathic pulmonary fibrosis
Chong, S. G., Yanagihara, T., & Kolb, M. R. J. (2020) · European Respiratory Society eBooks · doi:10.1183/2312508x.10028319 · Cited by 2
Azuma, A., & Richeldi, L. (2020) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2020.0005 · Cited by 2
Self-citationPhase three clinical trials in idiopathic pulmonary fibrosis
Sgalla, G., Lerede, M., & Richeldi, L. (2021) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2021.1882299 · Cited by 2
Self-citationFarrell, J., & Ho, L. A. (2023) · Integrated Pharmacy Research and Practice · doi:10.2147/iprp.s399518 · Cited by 2
Chang, Y., Tsai, M., Chang, Y.-P., Liao, C.-C., Lin, Y.-T., Lai, C., Lin, M., & Huang, K.-T. (2024) · Drugs - Real World Outcomes · doi:10.1007/s40801-024-00443-0 · Cited by 2
Deng, X., Liu, J., Zhou, J., Shi, Y., Song, S., Chen, J., Li, Y., Yu, B., Liang, S. H., & Zhu, X. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00571 · Cited by 2
Itano, J., Ishiga, M., Fujii, M., Takemoto, M., Hayashibara, N., Kimura, G., & Tanimoto, Y. (2025) · Internal Medicine · doi:10.2169/internalmedicine.4493-24 · Cited by 2
Wang, Y., Fan, W., Guo, Y., Sun, L., Hu, Y., Chen, J., Gong, L., & Xie, Z. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117768 · Cited by 2
Yanalak, A., & Yazıcı, O. (2025) · Thoracic research and practice · doi:10.4274/thoracrespract.2025.2025-3-5 · Cited by 4
Singh, P., Thampi, G., Gupta, K., Gangte, N., PATTNAIK, B. R., Agrawal, A., & Kukreti, R. (2025) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2025.2543473 · Cited by 3
Joos, G., & Gabazza, E. C. (2014) · Respirology · doi:10.1111/resp.12438 · Cited by 2
Anti-Angiogenesis, Gene Therapy, and Immunotherapy in Malignant Gliomas
Province, P., Shaefer, A. B., McCullough, B., & Fathallah‐Shaykh, H. M. (2014) · InTech eBooks · doi:10.5772/58320 · Cited by 2
New approaches to the design of clinical trials in idiopathic pulmonary fibrosis
Cerri, S., Giovane, C. D., Balduzzi, S., Soncini, F., Sdanganelli, A., & Richeldi, L. (2013) · Clinical Investigation · doi:10.4155/cli.13.39 · Cited by 2
Self-citationHanda, T., & Azuma, A. (2015) · Springer eBooks · doi:10.1007/978-4-431-55582-7_9 · Cited by 2
Current and Future Therapies for Idiopathic Pulmonary Fibrosis
Spagnolo, P., Bonella, F., Vašáková, M., Kreuter, M., & Maher, T. M. (2015) · Pulmonary Therapy · doi:10.1007/s41030-015-0009-4 · Cited by 2
Yamaguchi, M., Seto, T., Furuya, A., Edagawa, M., Shimamatsu, S., Toyozawa, R., Toyokawa, G., Nosaki, K., Hirai, F., Takenoyama, M., et al. (2016) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2016.08.011 · Cited by 2
Discovery and Development of Nintedanib: A Novel Antiangiogenic and Antifibrotic Agent
Roth, G. J., Binder, R., Colbatzky, F., Dallinger, C., Schlenker‐Herceg, R., Hilberg, F., Wollin, L., Park, J., Pautsch, A., & Kaiser, R. (2016) · Wiley eBooks · doi:10.1002/9783527800315.ch11 · Cited by 2
Approved and Experimental Therapies for Idiopathic Pulmonary Fibrosis
Pasciuto, G., Inchingolo, R., Condoluci, C., Magnini, D., Iovene, B., & Richeldi, L. (2018) · Current Pulmonology Reports · doi:10.1007/s13665-018-0209-0 · Cited by 2
Self-citationCarrera, L. G., & Walther, R. Á.-S. (2015) · Medicina Clínica · doi:10.1016/j.medcli.2015.06.002 · Cited by 2
Novel drug targets in idiopathic pulmonary fibrosis
Calvello, M., Flore, M. C., & Richeldi, L. (2019) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2019.1590196 · Cited by 2
Self-citationFujita, R., Iwasawa, T., Aoki, T., Iwao, Y., Ogura, T., & Utsunomiya, D. (2020) · Acta Radiologica · doi:10.1177/0284185120902393 · Cited by 2
Tratamiento farmacológico en la fibrosis pulmonar idiopática. Drogas modificadoras de enfermedad
FLORENZANO, M., V, & C, F. R. (2019) · Revista chilena de enfermedades respiratorias · doi:10.4067/s0717-73482019000400287 · Cited by 3
Antifibrotic Therapy: Is There a Role in Myositis-Interstitial Lung Disease?
Soskis, A., & Hallowell, R. W. (2021) · Respiration · doi:10.1159/000515607 · Cited by 2
Kafle, S., Magar, M. T., Patel, P., Poudel, A., & Cancarevic, I. (2021) · Cureus · doi:10.7759/cureus.16404 · Cited by 2
Wilson, A. M., Clark, A., Cahn, A. P., Chilvers, E. R., Fraser, W. D., Hammond, M., Livermore, D. M., Maher, T. M., Parfrey, H., Swart, A. M., et al. (2021) · Efficacy and Mechanism Evaluation · doi:10.3310/eme08090 · Cited by 3
Abraham, B. P., & Sellin, J. H. (2019) · Wiley eBooks · doi:10.1002/9781119211419.ch14 · Cited by 2
Idiopathic Pulmonary Fibrosis: The Epidemiology and Natural History of Disease
Mohning, M. P., Swigris, J. J., & Olson, A. L. (2018) · Respiratory medicine · doi:10.1007/978-3-319-99975-3_2 · Cited by 2
Developments in the management of idiopathic pulmonary fibrosis
(2015) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2015.7.0337 · Cited by 2
Neumonías intersticiales idiopáticas
Velasco, D., Alonso, I. J., Bobillo, J. R., & Oriol, A. J. (2022) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2022.09.011 · Cited by 2
Feshchenko, Y. I., Gavrysyuk, V. K., Горовенко, Н. Г., Dziublyk, O., Pertseva, T. O., Ostrovsky, M. M., Basanets, A. V., Bychenko, O. V., Dziublyk, Y. O., Konopkina, L., et al. (2023) · Ukrainian Pulmonology Journal · doi:10.31215/2306-4927-2023-31-1-5-33 · Cited by 4
Inhaled nintentanib, Pirfenidone and Macitentan for Pulmonary Fibrosis: a Laboratory Experiment
Zarogoulidis, P., Petridis, D., Huang, H., Bai, C., Oikonomou, P., Nikolaou, C., Matthaios, D., Perdikouri, Ε.-I., Papadopoulos, V., Petanidis, S., et al. (2023) · Therapeutic Delivery · doi:10.4155/tde-2023-0045 · Cited by 2
Üzer, F., AKANLAR, S., & Çilli, A. (2023) · Tuberkuloz ve Toraks · doi:10.5578/tt.20239603 · Cited by 4
Importance of Idiopathic Pulmonary Fibrosis Staging for Clinical Trial Endpoints
O’Connell, O. J., Riddell, P., & Egan, J. J. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201208-1555le · Cited by 2
Safety management of treatment with nintedanib in clinical practice of IPF
Azuma, A. (2016) · Respiratory Investigation · doi:10.1016/j.resinv.2016.12.001 · Cited by 2
Idiopathic pulmonary fibrosis: The current state of the problem
Shmelev, E. I. (2016) · Terapevticheskii arkhiv · doi:10.17116/terarkh20168812103-108 · Cited by 2
Is nintedanib effective for idiopathic pulmonary fibrosis?
Jeldres, A., & Gonzalo Labarca, T. (2017) · Medwave · doi:10.5867/medwave.2017.6918 · Cited by 2
Trial of a Phosphodiesterase 4 Inhibitor for Idiopathic Pulmonary Fibrosis. Reply.
Richeldi, L., Stowasser, S., & Maher, T. M. (2022) · PubMed · doi:10.1056/nejmc2209529 · Cited by 1
Self-citationHeymach, J. V., Zurita‐Saavedra, A., Kopetz, S., Cascone, T., Nilsson, M. B., & Guijarro, I. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm017.pub2 · Cited by 2
Idiopathic pulmonary fibrosis: What has changed in the diagnosis and treatment from past to present?
Anar, C. M., Okutan, O., Şengül, A., Yazıcı, O., & Altınsoy, B. (2020) · Eurasian Journal of Pulmonology · doi:10.4103/ejop.ejop_45_19 · Cited by 1
Metadata
- Authors
- Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., Brun, M., Gupta, A., Juhel, N., Klüglich, M., & du Bois, R. M.
- Affiliations
- University of Modena and Reggio Emilia (IT)
- Ruhrlandklinik (DE)
- Asan Medical Center (KR)
- Royal Brompton Hospital (GB)
- Michigan Medicine (US)
- Duke Medical Center (US)
- University of Washington (US)
- Boehringer Ingelheim (France) (FR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-09-22
- Volume
- 365
- Issue
- 12
- Pages
- 1079-1087
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2152974152
- Cited by
- 1,157
- References
- 22
- Citations by year
- 2026: 32 · 2025: 50 · 2024: 79 · 2023: 74 · 2022: 83 · 2021: 86 · 2020: 73 · 2019: 72 · 2018: 91 · 2017: 102 · 2016: 88 · 2015: 100 · 2014: 71 · 2013: 80 · 2012: 61
- FWCI
- 60.67
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- idiopathic pulmonary fibrosis, nintedanib, tyrosine kinase inhibitors, forced vital capacity decline, lung fibrosis progression, acute exacerbation, quality of life, gastrointestinal adverse effects, liver aminotransferases, dose comparison, St George's Respiratory Questionnaire, total lung capacity, drug safety and efficacy
- MeSH terms
- Adult, Aged, Alanine Transaminase, Aspartate Aminotransferases, Enzyme Inhibitors, Female, Humans, Indoles, Liver, Male, Middle Aged, Protein-Tyrosine Kinases, Vital Capacity, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.